Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win

Summary

Article references a competitive showdown between Eli Lilly and Novo Nordisk at the EASD conference in Milan and discusses potential ETF implications. No specific drug data, trial results, or financial information are provided in the available text.